The historical rank and industry rank for Peterlabs Holdings Bhd's Net Margin % or its related term are showing as below:
XKLS:0171'
s Net Margin % Range Over the Past 10 Years
Min: 0.54 Med: 4.22 Max: 5.51
Current: 0.54
XKLS:0171's Net Margin % is ranked worse than 65.38% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XKLS:0171: 0.54
Peterlabs Holdings Bhd (XKLS:0171) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Peterlabs Holdings Bhd Net Margin % Related Terms
Peterlabs Holdings Bhd Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0171 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Net Margin % distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a Net Margin % of -4.34% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Peterlabs Holdings Bhd and its competitors. Over the past decade, Peterlabs Holdings Bhd's Net Margin % has ranged from 0.54 to 5.51. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #625 out of 956 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Peterlabs Holdings Bhd's Net Margin % too high?
Peterlabs Holdings Bhd's current Net Margin % is -4.34%. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 5.51. Based on the distribution chart, Peterlabs Holdings Bhd ranks #625 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #625 out of 956 companies for Net Margin %. This places Peterlabs Holdings Bhd in the lower half of its industry. The industry median Net Margin % is 5.56. Historically, Peterlabs Holdings Bhd's own Net Margin % has ranged from 0.54 to 5.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Net Margin % is -4.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 17.5% above its estimated fair value. The current Net Margin % is -4.34%. Peterlabs Holdings Bhd's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Net Margin % is -4.34% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued.
The current stock price of RM0.24 is trading 17.5% above its estimated GF Value™ of RM0.20.
GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0171:
Net Margin %: -4.34%
GF Value™: RM0.20 vs. price of RM0.24 (17.5% above fair value)
No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
46GF Score
Get the complete analysis for XKLS:0171
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
